Insider Selling: Danaher Co. (NYSE:DHR) Director Sells $1,166,415.30 in Stock

Danaher Co. (NYSE:DHR) Director John T. Schwieters sold 6,014 shares of Danaher stock in a transaction that occurred on Friday, July 24th. The stock was sold at an average price of $193.95, for a total value of $1,166,415.30. Following the transaction, the director now owns 25,394 shares of the company’s stock, valued at $4,925,166.30. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of NYSE DHR opened at $202.14 on Friday. The stock has a market capitalization of $141.34 billion, a PE ratio of 43.28, a P/E/G ratio of 3.19 and a beta of 0.92. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.20 and a quick ratio of 1.74. The business has a fifty day moving average price of $181.65 and a two-hundred day moving average price of $161.73. Danaher Co. has a fifty-two week low of $119.60 and a fifty-two week high of $204.13.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Thursday, July 23rd. The conglomerate reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.35. Danaher had a return on equity of 11.88% and a net margin of 17.73%. The company had revenue of $5.30 billion during the quarter, compared to analysts’ expectations of $5.01 billion. During the same quarter in the previous year, the firm earned $1.09 EPS. Danaher’s revenue was up 2.7% on a year-over-year basis. On average, equities analysts expect that Danaher Co. will post 5.36 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a dividend of $0.18 per share. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.36%. Danaher’s dividend payout ratio (DPR) is currently 16.29%.

Several institutional investors have recently bought and sold shares of DHR. Lion Street Advisors LLC acquired a new position in shares of Danaher during the 1st quarter worth $25,000. Archer Investment Corp acquired a new position in shares of Danaher during the 4th quarter worth $27,000. Howe & Rusling Inc. raised its holdings in shares of Danaher by 81.4% during the 2nd quarter. Howe & Rusling Inc. now owns 156 shares of the conglomerate’s stock worth $28,000 after buying an additional 70 shares in the last quarter. Manchester Financial Inc. raised its holdings in shares of Danaher by 50.0% during the 1st quarter. Manchester Financial Inc. now owns 228 shares of the conglomerate’s stock worth $32,000 after buying an additional 76 shares in the last quarter. Finally, Semmax Financial Advisors Inc. acquired a new position in shares of Danaher during the 2nd quarter worth $35,000. 77.67% of the stock is owned by institutional investors.

DHR has been the subject of several recent research reports. Bank of America boosted their price target on Danaher from $181.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, July 20th. UBS Group boosted their price target on Danaher from $176.00 to $233.00 and gave the company a “buy” rating in a research note on Monday. Royal Bank of Canada boosted their price target on Danaher from $205.00 to $218.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $203.00 price target for the company in a research note on Tuesday, July 21st. Finally, Stifel Nicolaus boosted their price target on Danaher from $170.00 to $210.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $197.73.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Read More: How to Use a Moving Average for TradingĀ 

Insider Buying and Selling by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.